A study for men with advanced prostate cancer on a specific clinical trial
Part of Cancer, Kidney & urinary clinical trials.
This study looks at men with metastatic castration-resistant prostate cancer who are already taking part in the SYNGERY-201 clinical trial. The goal is to understand how treatments work and how to best support patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (over 18 years old).
- You have metastatic castration-resistant prostate cancer (cancer that has spread and is no longer responding to hormone therapy).
- You are already enrolled in the SYNGERY-201 clinical trial (a specific study).
- You must be willing to give written permission (informed consent) to join this study and allow your health information to be used.
- You should not have any other medical condition, treatment, or lab result that could confuse the study results or make it unsafe for you to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
This trial tests a new drug, SHR-4394, for men with prostate cancer that has spread to other parts of the body and is no longer responding to current treatments. The goal is to see if this drug can help slow down the cancer.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new treatment called SYNC-T Therapy (SV-102) for men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The therapy is given directly into a tumor to help your immune system fight the cancer.
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.